CAR-T cell therapy development is a complex process that requires standardization.
Mark White
Advertisement
Mark White, PhD, is the associate director of Biopharma Product Marketing at Bio-Rad.
Articles by Mark White
Advertisement
Latest Updated Articles
Assessing the Quality of CAR-T Cells Using ddPCRMarch 15th 2022
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
2
Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3
3
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
4
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
5